Reliable Brokers
Online Investing
Alerts & Analysis
Easy Trading

Abingdon Health (LON: ABDX) has an actually useful product - pregnancy tests in Tesco

Not that anyone actually needs to know while in Tesco of course but you grasp the point.

Update : 15 Aug 2023, 11:40 PM

Abingdon Health (LON: ABDX) shares are up 25% this morning. ABDX shares have risen on the launch of a saliva based pregnancy test in Tesco. This is, as long term holders of Abingdon will be glad to note, an actual product which people voluntarily buy. Which is one of those innovations for the company. 

OK, that’s just us being cynics. But Abingdon Health has not done well by shareholders these past few years. The reason being that it came to market in the middle of all that fuss about covid, lockdown and the absence of testing kits. So, testing kits were designed and rolled out - but they came rather late. The big, juicy, government contracts had already gone by the time it was ready. There were also problems with the actual efficacy of the tests themselves. There were several companies in this sort of position on the London market. We even saw a near coordinated rise in them as they all declared that had achieved CE Marks - without quite pointing out that a CE mark is not like an FDA approval, it’s just self-certification and the payment of the relevant fee.

Still, all that’s in the past.  

Abingdon Health share price from Google Finance

Now that all that is behind us - and Abingdon - there’s the possibility to gain a reasonable view of the sensible valuation. Here, the new product: “Abingdon Health is the exclusive distributor of Salistick™ in the UK and Ireland on behalf of Salignostics Limited, an Israeli developer of innovative saliva-based diagnostics tests. As well as providing distribution support Abingdon Health has been providing Salignostics with contract development services to scale-up the Salistick™ product for manufacture and will continue to provide Salignostics with contract manufacturing services going forward.”

Ah, it’s a distribution agreement. Well, there’s money in distribution if it’s done well. But it is qualitatively different from marketing a test which is fully owned - and where the value of the IP flows back to Abingdon.

We’re willing to believe that this will do well. Believe though - we’re going to wait and see. It’s also possible that the strategy, of being a distributor not originator will work. That’s also one of those things we’re willing to await. Our real problem here is that previous performance doesn’t give us great confidence in future. A bit unkind of us perhaps but there it is.

Top Brokers